title: Gastrointestinal bleeding secondary to the new anticoagulants.
abstract: To quantify direct oral anticoagulants (DOACs) related gastrointestinal bleeding (GIB), characterize patients at greatest risk and provide a pragmatic approach for the management of these drugs. This review will also summarize risk-management strategies and highlight evolving areas of clinical knowledge.
  
  
  
  DOACs permit anticoagulation with predictable dosing without the need for routine serum monitoring. Since their availability on the market, they have quickly emerged as a popular alternative for patients requiring short-term and lifelong anticoagulation. However, they are associated with an increased risk of GIB when compared with warfarin; thus, gastroenterologists must be prepared to manage DOAC-related GIB and prevent drug-related complications. This review will focus on acute and elective periendoscopic DOAC management, high-risk clinical groups for DOAC-related GIB, quantification of DOAC levels, use of reversal agents and minimization of thromboembolic risk associated with temporary interruption.
  
  
  
  This review will highlight pragmatic strategies for the treatment of DOAC-related bleeding and the prevention of postendoscopic DOAC bleeding. It will address new and evolving areas of periendoscopic management and identify knowledge gaps requiring further research to inform clinical practice.
authors.affiliation: aDivision of Gastroenterology, Department of Medicine, Mayo Clinic, Scottsdale, Arizona bDivision of Health Care Policy and Research, Department of Health Services Research, Rochester, Minnesota, United States.
authors.forename: Neena S
authors.initials: NS
authors.lastname: Abraham
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Horsley-Silva
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D016903:Drug Monitoring / Q000379:methods; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced* / Q000628:therapy; D005919:Glomerular Filtration Rate; D006489:Hemostatic Techniques; D006801:Humans; D018570:Risk Assessment / Q000379:methods; D012307:Risk Factors
chemical_list: D000925:Anticoagulants